FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approved Novo Nordisk's supplemental application for Wegovy (semaglutide), updating the approval to support its chronic weight-management indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Obesity in Adolescents
• Overweight

Drugs mentioned

• WEGOVY (Semaglutide)

Snippet

SUPPL AP for WEGOVY (SEMAGLUTIDE)